Stockreport

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

LAVA Therapeutics N.V. - Ordinary Shares  (LVTX) 
PDF LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical [Read more]